Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue.
暂无分享,去创建一个
J. Taube | E. Jaffee | Lieping Chen | R. Anders | Haiying Xu | K. Bever | Lei Zheng | Annie A Wu | Elaine O Bigelow | Allison Yager | L. Zheng | Lei Zheng
[1] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[2] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Min Zhang,et al. Clinical Significance of B7-H1 and B7-1 Expressions in Pancreatic Carcinoma , 2010, World Journal of Surgery.
[4] S. H. van der Burg,et al. Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma , 2009, Clinical Cancer Research.
[5] M. Azuma,et al. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. , 2009, International journal of oncology.
[6] H. Friess,et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. , 2008, Cancer letters.
[7] Shusen Zheng,et al. B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression , 2008, Journal of Cancer Research and Clinical Oncology.
[8] Haidong Dong,et al. PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata , 2007, Cancer.
[9] M. Azuma,et al. Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer , 2007, Clinical Cancer Research.
[10] Lieping Chen,et al. The new B7s: playing a pivotal role in tumor immunity. , 2007, Journal of immunotherapy.
[11] R. Thompson,et al. Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy , 2007, Clinical Cancer Research.
[12] J. Cheville,et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.
[13] J. Cheville,et al. B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma. , 2005, Urology.
[14] G. Zhu,et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.
[15] J. Cheville,et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. , 2003, Cancer research.
[16] T. Curiel,et al. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.
[17] Lieping Chen,et al. B7-H1 pathway and its role in the evasion of tumor immunity , 2003, Journal of Molecular Medicine.
[18] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[19] G. Zhu,et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.
[20] Lieping Chen,et al. Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways. , 2011, Current topics in microbiology and immunology.